NMTR vs. EIGR, SBFM, SINT, ACORQ, VRAX, BBLG, EVLO, SPRC, TCBP, and EVFM
Should you be buying 9 Meters Biopharma stock or one of its competitors? The main competitors of 9 Meters Biopharma include Eiger BioPharmaceuticals (EIGR), Sunshine Biopharma (SBFM), Sintx Technologies (SINT), Acorda Therapeutics (ACORQ), Virax Biolabs Group (VRAX), Bone Biologics (BBLG), Evelo Biosciences (EVLO), SciSparc (SPRC), TC Biopharm (TCBP), and Evofem Biosciences (EVFM). These companies are all part of the "medical" sector.
Eiger BioPharmaceuticals (NASDAQ:EIGR) and 9 Meters Biopharma (NASDAQ:NMTR) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their community ranking, risk, institutional ownership, earnings, dividends, media sentiment, valuation, profitability and analyst recommendations.
62.5% of Eiger BioPharmaceuticals shares are held by institutional investors. Comparatively, 22.3% of 9 Meters Biopharma shares are held by institutional investors. 4.2% of Eiger BioPharmaceuticals shares are held by insiders. Comparatively, 2.4% of 9 Meters Biopharma shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Eiger BioPharmaceuticals received 377 more outperform votes than 9 Meters Biopharma when rated by MarketBeat users. However, 71.15% of users gave 9 Meters Biopharma an outperform vote while only 67.54% of users gave Eiger BioPharmaceuticals an outperform vote.
In the previous week, Eiger BioPharmaceuticals had 1 more articles in the media than 9 Meters Biopharma. MarketBeat recorded 1 mentions for Eiger BioPharmaceuticals and 0 mentions for 9 Meters Biopharma. 9 Meters Biopharma's average media sentiment score of 0.17 beat Eiger BioPharmaceuticals' score of 0.00 indicating that Eiger BioPharmaceuticals is being referred to more favorably in the media.
Eiger BioPharmaceuticals presently has a consensus price target of $120.00, suggesting a potential upside of ∞. 9 Meters Biopharma has a consensus price target of $1.70, suggesting a potential upside of ∞.
9 Meters Biopharma has a net margin of 0.00% compared to 9 Meters Biopharma's net margin of -590.80%. 9 Meters Biopharma's return on equity of -332.49% beat Eiger BioPharmaceuticals' return on equity.
9 Meters Biopharma has lower revenue, but higher earnings than Eiger BioPharmaceuticals.
Eiger BioPharmaceuticals has a beta of 1.83, meaning that its share price is 83% more volatile than the S&P 500. Comparatively, 9 Meters Biopharma has a beta of 1.36, meaning that its share price is 36% more volatile than the S&P 500.
Summary
Eiger BioPharmaceuticals beats 9 Meters Biopharma on 11 of the 16 factors compared between the two stocks.
Get 9 Meters Biopharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for NMTR and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding NMTR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
9 Meters Biopharma Competitors List
Related Companies and Tools
